Maria Viktorovna Yusenko (Maria V Yusenko)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Autism Spectrum Disorder

Top Venues

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Rosa Catalina Lederbogen, Sabine Hoffjan, Charlotte Thiels, Ulrike Angelika Mau-Holzmann, Sylke Singer, Maria Viktorovna Yusenko, Hoa Huu Phuc Nguyen, Wanda Maria Gerding
Optical Genome Mapping Reveals Disruption of the RASGRF2 Gene in a Patient with Developmental Delay Carrying a De Novo Balanced Reciprocal Translocation. Genes 15 (6) (2024)
Rosa Catalina Lederbogen, Sabine Hoffjan, Charlotte Thiels, Ulrike Angelika Mau-Holzmann, Sylke Singer, Maria Viktorovna Yusenko, Hoa Huu Phuc Nguyen, Wanda Maria Gerding
Optical Genome Mapping Reveals Disruption of the RASGRF2 Gene in a Patient with Developmental Delay Carrying a De Novo Balanced Reciprocal Translocation. Genes 15 (6) (2024)
Rosa Catalina Lederbogen, Sabine Hoffjan, Charlotte Thiels, Ulrike Angelika Mau-Holzmann, Sylke Singer, Maria Viktorovna Yusenko, Hoa Huu Phuc Nguyen, Wanda Maria Gerding
Optical Genome Mapping Reveals Disruption of the RASGRF2 Gene in a Patient with Developmental Delay Carrying a De Novo Balanced Reciprocal Translocation. Genes 15 (6) (2024)
Lehel Peterfi, Maria Viktorovna Yusenko, Gyula Kovacs, Tamas Beothe
Lack of VEGFA/KDR Signaling in Conventional Renal Cell Carcinoma Explains the Low Efficacy of Target Therapy and Frequent Adverse Events. International journal of molecular sciences 25 (13) (2024)
Lehel Peterfi, Maria Viktorovna Yusenko, Gyula Kovacs, Tamas Beothe
Lack of VEGFA/KDR Signaling in Conventional Renal Cell Carcinoma Explains the Low Efficacy of Target Therapy and Frequent Adverse Events. International journal of molecular sciences 25 (13) (2024)
Lehel Peterfi, Maria Viktorovna Yusenko, Gyula Kovacs, Tamas Beothe
Lack of VEGFA/KDR Signaling in Conventional Renal Cell Carcinoma Explains the Low Efficacy of Target Therapy and Frequent Adverse Events. International journal of molecular sciences 25 (13) (2024)